Controversy
Status:Open
Will annual global sales of GLP-1-based anti-obesity and diabetes drugs exceed $100 billion by 2028?
UNLIKELYLIKELY
Claims
Fortune Business Insights"The global anti-obesity drugs market size was valued at USD 4.51 billion in 2023 and is projected to grow from USD 6.15 billion in 2024 to USD 37.94 billion by 2032, exhibiting a CAGR of 25.5% during the forecast period (2024-2032)."Nov 10, 2025
Fierce Pharma"By 2029, annual sales of GLP-1s are forecasted to surpass the $100 billion mark."Nov 26, 2025
Gabelli"We estimate about 12-15 million patients will be using GLP-1 drugs by 2030 across both indications, which translates to the market growing from ~$30B today to ~$80B by 2030."Apr 01, 2025
TD Securities"Global GLP-1 sales in 2030 could reach US$139 billion, up from our US$101 billion forecast a little over a year ago."Nov 26, 2025
UBS Global Wealth Management"This [GLP-1 model forecast] translates into $126bn sales by 2029, a 2023-2029 sales CAGR of 30%."Nov 26, 2025
William Blair"Taking into account obesity and its associated comorbidities, we estimate that anti-obesity medication could reach over $100 billion in global sales [in the next 10 years], pending a more accommodative reimbursement landscape."Nov 26, 2025
MarketsandMarkets"The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period."Nov 17, 2025
Daniel Chancellor"With late-stage clinical trials in a range of additional diseases, and a patient impact that rivals that of the statins, GLP-1 sales of $100 billion by 2030 may actually be a temporary ceiling."Jul 10, 2024
Grand View Research"The global GLP-1 agonists weight loss drugs market size was estimated at USD 13.84 billion in 2024 and is projected to reach USD 48.84 billion by 2030, growing at a CAGR of 18.54% from 2025 to 2030."Nov 26, 2025
Roots Analysis"The global GLP-1 market, valued at USD 49.3 billion in 2024, is estimated to reach USD 62.2 billion in 2025 and USD 157.5 billion by 2035, representing a CAGR of 9.7% during the forecast period."Nov 04, 2025
Goldman Sachs"By 2030, it [the GLP-1 market] could grow by more than 16 times to $100 billion."Oct 30, 2023
Edgen"The obesity therapeutics market is projected for significant expansion, targeting $20.84 billion by 2033 with a compound annual growth rate of 20.6%."Nov 26, 2025
Precedence Research"The global GLP-1 analogues market size was calculated at USD 49.90 billion in 2024 and is predicted to increase from USD 66.48 billion in 2025 to approximately USD 879.90 billion by 2034, expanding at a CAGR of 33.24% from 2025 to 2034."Sep 01, 2025
Morgan Stanley"Morgan Stanley Research has re-evaluated the global market for obesity drugs and is now expecting it to reach $105 billion in 2030, up from an earlier forecast of $77 billion—and as high as $144 billion."Nov 26, 2025
Cloudwalker"Continued growth in Ozempic and Zepbound sales is needed to be seen by the market to validate a $150B market by 2030."Nov 26, 2025
© 2025 Improve the News Foundation. All rights reserved.Version 6.18.0
© 2025 Improve the News Foundation.
All rights reserved.
Version 6.18.0